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THESIS ABSTRACT 
Introduction 
 Neutralizing antibodies play an important role in protection against dengue 
virus (DENV) infection. Current tetravalent dengue vaccine against all four serotypes 
of DENV was developed using only single genotype from each serotype, with the 
assumption that infection with one genotype within the same serotype will induce 
protection against all genotypes within the same serotype. It is widely believed that 
despite antigenic differences, neutralizing antibody epitopes are conserved among the 
strains within the same serotypes and strain variation does not affect the ability of 
neutralizing antibodies to confer protection. Nonetheless, the efficacy of tetravalent 
vaccine is varied by infected virus, and the efficacy of DENV-2 vaccine is the lowest 
among four serotypes. Studies on the levels of genotype-specific and genotype cross-
reactive neutralizing antibodies to genotypes of DENV are still limited.  In addition, 
studies on correlation between antigenic differences in genotypes and levels of viremia 
and cell-mediated immunity during DENV infection are limited as well.  
 
This present study aims to (i) determined the levels of genotype-specific and 
genotype cross-reactive neutralizing antibody in response to DENV-2 in primary, 
secondary, and tertiary DENV infections in common marmosets (Callithrix jacchus) 
model; (ii) determined levels of viremia and immune-related genes upon inoculation 
with different genotypes and serotypes of DENV in primary, secondary, and tertiary 
infections in common marmosets (Callithrix jacchus) model.  
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Materials and Methods 
 In study (i), a total of 59 plasma samples were obtained from 34 common 
marmosets that, were either inoculated with clinically-isolated virus strains (N=26), or 
inoculated with candidate vaccine strain (N=8). Plasma samples were obtained from 
marmosets after primary, secondary, or tertiary infection of DENV. There were 12 
groups of marmosets that were inoculated with clinically-isolated virus strains and 5 
groups of marmosets that were inoculated with candidate vaccine strains. The levels of 
neutralizing antibodies to DENV-2 Cosmopolitan, Asian I, and Asian/American 
genotypes and DENV-1 were determined using a conventional plaque reduction 
neutralization assay on day 0 (prior to virus inoculation), 4, 7, and 14 post-inoculation. 
Student’s t-test was used to determine the differences in mean titers of neutralizing 
antibody between genotypes of each group. 
 
 In study (ii), a total of 19 plasma and peripheral blood mononuclear cells 
samples were collected on days 0 (prior to virus inoculation), 2, 4, 7, 10, and 14 post-
inoculation from 7 groups of common marmosets. There were 2 groups of marmosets 
for primary infection (N=6), 3 groups of marmosets for secondary infection (N=7), and 
2 groups of marmosets for tertiary infection (N=6). Viral RNA copy numbers and 
infectious virus titers were determined using quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) and conventional plaque assay, respectively. 
Levels of immune-related genes including CD3, CD4, CD8, IFN, IL-1IL-2, and 
IL-10 were determined using qRT-PCR. Expression levels of each gene were analyzed 
using comparative CT method and normalized with levels of GAPDH as reference gene. 
Differences in levels of immune-related gene on days 2, 4, 7, 10, and 14 p.i were 
compared with those on day 0 as a reference using Student’s t-test.  
 iii 
Results 
 Neutralizing antibodies induced during primary DENV-2 infection neutralized 
all three genotypes of DENV-2 (Cosmopolitan, Asian I, and Asian/American 
genotypes). In secondary infection with homologous genotype, levels of genotype-
specific and genotype cross-reactive neutralizing antibodies to all three genotypes of 
DENV-2 did not differ from days 0-14 post-inoculation in marmosets that were 
inoculated with DENV-2 Cosmopolitan and Asian I genotypes but not in marmosets 
that were inoculated with DENV-2 Asian/American genotype. Higher levels of 
neutralizing antibodies to Asian/American genotype than those to Cosmopolitan and 
Asian I genotypes were observed in secondary infection with heterologous genotype 
and in tertiary infection. Single infection with DENV-1 did not induce serotype cross-
reactive neutralizing antibodies to DENV-2, and following secondary DENV-1 
infection, serotype cross-reactive neutralizing antibodies to DENV-2 were induced. 
Levels of neutralizing antibodies in marmosets that were inoculated with candidate 
vaccine strain were comparable as those marmosets that were inoculated with clinically 
isolated parent strain.  
 
 Levels of viremia in primary and tertiary DENV infection were different upon 
inoculation with different genotypes of DENV. In secondary infection, viremia was 
detected in marmosets that were inoculated with heterologous serotype but absent in 
those that were inoculated with homologous serotype. Levels of CD3, CD4, IFN, IL-
2, and IL-10 in all groups of marmosets differed. Interestingly, levels of CD8 
decreased in early phase of viremia and increased in late phase of viremia. Levels of 
IL-1 decreased in all marmosets that developed viremia following DENV infection. 
 
 iv 
Discussion 
 Neutralizing antibodies induced during primary infection were genotype cross-
reactive but serotype-specific. Differences in levels of neutralizing antibodies during 
heterologous infection suggest heterogeneity in antigenic molecules among genotypes 
may lead to the induction of higher levels of neutralizing antibodies. Sequential 
infection induced broad cross-reactive neutralizing antibodies that neutralized multiple 
serotypes including non-infecting serotypes. Heterogeneity and homogeneity of 
infecting genotype influence the levels and cross-reactivity of neutralizing antibodies 
that were induced in following infections. Study on candidate vaccine strain suggested 
that while attenuation decreased the virus pathogenicity, immunogenicity patterns 
between genotypes retained. Differences in the levels of viremia may have been caused 
by antigenic differences. Nonetheless, the correlation between antigenic differences in 
genotypes of DENV and levels of immune-related genes remained inconclusive. Levels 
of CD8 inversely correlated with viremia levels, because CD8+ T cells may have been 
activated to control the viral replication. Decreased levels of IL-1 in marmosets maybe 
associated in the absence of vascular permeability symptoms.  
 
Conclusion 
 Levels and patterns of genotype-specific and genotype cross–reactive 
neutralizing antibodies, and viremia levels were different in primary, secondary and 
tertiary DENV infection in common marmosets. Thus, identification of DENV strains 
that able to induce similar levels of neutralizing antibodies and offer protection against 
homologous or heterologous genotypes of DENV should be addressed in DENV 
vaccine development study. 
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CHAPTER 1: LITERATURE REVIEW 
1.1. Dengue virus   
The word “Dengue” (DEN) is originated from the Swahili phrase “ki dinga pepo” 
which means a “kind of sudden cramp-like seizure from an evil spirit or plague”1. 
Dengue virus (DENV) belongs to genus Flaviviridae of the family Flavivirus. The 
genus Flaviviridae comprised of DENV, Japanese encephalitis virus, yellow fever virus 
and West Nile virus. This virus is usually transmitted to human by Aedes aegypti and 
Aedes albopictus mosquitoes2,3. 
 
 DENV is a small, enveloped virus that contains a single-stranded, positive sense 
RNA genome2,4–6. The RNA genome of DENV (-11,000 nt) is made up of a single open 
reading frame that encodes for three structural proteins: capsid (C), pre-membrane 
(prM) and envelope (E), and seven non-structural protein: NS1, NS2a, NS2b, NS3, 
NS4a, NS4b and NS54,7,8. The C and prM proteins mediate in the encapsidation of RNA 
genome, and the release of mature virion, respectively9. The E protein facilitates in 
virus binding, fusion of viral to host cellular membranes during viral entry and in the 
stimulation of host protective immunity3,5,9. Individual subunits of E protein composed 
of three beta-barrel domains: envelope domains I, II, and III (EDI, EDII, and EDIII, 
respectively)10,11. EDIII domain has been correlated with a strong neutralization 
activity3. The viral envelope contains two integral membrane proteins, E and prM 
protein, and these proteins are the main target of immune response during DENV 
infection5,11. The non-structural proteins were responsible in the replication of viral 
genome but not detectable in viral proteins.  
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1.2. Serotype of dengue virus  
There are four serotypes of DENV; DENV1, DENV-2, DENV-3, and DENV-4. 
The definition of serotype is based on the observation that full protection was conferred 
against infection with homologous viruses but limited protection against heterologous 
viruses 9,12. Differences in amino acid sequences in EDIII domain in E protein provide 
the basis for the antigenically distinct serotypes of DENV10. The homology among 
serotypes is less than 60% at the nucleotide levels and less than 80% at the amino acid 
levels13,14. All four DENV serotypes have similar clinical symptoms and co-circulate 
in endemic areas. Nonetheless, outbreaks of DENV-2 and DENV-3 were often 
associated with severe dengue and outbreaks of DENV-1 and DENV-4 were often 
associated with more mild diseases. DENV-2 is the most prevalent serotype in the 
current worldwide dengue epidemic15.  
 
1.3.  Genotype of dengue virus 
Phylogenetic analysis of the E protein revealed that each DENV serotype has 4-6 
genotypes. Genotype is defined as clusters of DENV with sequence divergence not 
greater than 6% within the chosen genome region (E/NS1 junction). The homology 
among genotypes within the same serotype is about 94-97%14. Antigenic differences 
among genotypes have been speculated played an important role in the severity of the 
diseases, epidemic magnitude, viral fitness and evolution, and vaccine design12,14.  
 
Genotypes of DENV-2 differed in term of virulence, incidence, and vector 
competence16–20. DENV-2 is divided into six genotypes: sylvatic, Cosmopolitan, Asian 
I, Asian II, Asian/American, and American genotypes 15,16. The Cosmopolitan genotype 
was associated with diverse range of geographical localities and severe dengue, and the 
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American genotype was associated with milder diseases 16,18. The viral fitness in the 
Asian I and Asian/American genotypes differed. Infection with the Asian I genotype 
induced higher levels of viremia than infection with the Asian/American genotype16,20. 
The differences in viral fitness lead to displacement of the Asian/American genotype 
to the Asian I genotype in Vietnam, Thailand, and Cambodia19. In term of vector 
competence, the Asian/American genotype was efficiently infected the salivary gland 
of Aedes mosquitoes than the American genotype17.  
 
1.4. Epidemiology of dengue 
DENV was first isolated in Nagasaki-Sasebo, Japan during the epidemic in 1942, 
by inoculating serum from acutely ill patients into suckling mice 21,22. Dengue (DEN) 
has become major public health threat in tropical and subtropical regions including 
Southeast Asia, Africa, South Pacific, Central and South American and Eastern 
Mediterranean23,24. In recent years, dengue outbreaks were reported in temperate places 
such as France, Croatia, Japan and China25–29.  
 
DENV had infected up to 4 billion people worldwide and 390 million new DENV 
infection cases were reported annually8,16,30,31. The incidences of DENV infection had 
increased up to 30-folds for the past 60 years14. Population growth, global urbanization, 
ease of transportation, expansion of vector geographical habitats and inadequate 
mosquito controls were factors that facilitated the emergence of dengue incidence28,32. 
World Health Organization (WHO) aimed to reduce mortality and morbidity of DEN 
by at least 50% and 25%, respectively in 202033.  
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1.5. Clinical features of dengue  
Infection with DENV can either be asymptomatic or symptomatic. The 2009 WHO 
DEN case classification categorized DEN cases based on disease severity levels34. 
Symptomatic cases of DENV infection ranged from mild febrile illness, dengue without 
warning signs, dengue with warning signs, to severe dengue and sometimes dengue-
related death. There are three phases of DEN illness: febrile phase which last for 3-7 
days, critical phase, and spontaneous recovery phase14,35. The symptoms usually start 
to manifest after the incubation period of 3-7 days35. While most patients recover after 
the febrile phase, a small proportion of the patients progress to severe dengue 
symptoms27.  
 
1.5.1. Dengue with or without warning signs 
Dengue fever (DF) is characterized by high-grade fever, headache, arthralgia, 
myalgia, rash, gastrointestinal discomfort, and retro-orbital pain27,36,37. Minor 
hemorrhagic manifestation occurs in the form of petechiae, epistaxis, gingival 
bleeding37. The progressive decrease in total white cell count during full blood count is 
sign of DF. Patients who recover following defervescence are considered as dengue 
without warning signs. Patients that were diagnosed as dengue with warning signs 
showed symptoms including abdominal pain, persistent vomiting, fluid accumulation, 
mucosal bleeding, lethargy, liver enlargement, increasing hematocrit with decreasing 
platelets34. 
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1.5.2. Severe Dengue  
About 1-6% of the symptomatic cases of DENV infections progress to severe38. 
The mortality rate of severe dengue is 2.5%, particularly in infants and children8,27. The 
1997 WHO DEN case classification categorized severe dengue into dengue 
hemorrhagic fever (Grades 1-2) and dengue shock syndrome (Grades 3-4). Dengue 
hemorrhagic fever (DHF) was diagnosed as DF with hemorrhagic manifestations 
including, plasma leakage resulting in shock, accumulation of serosal fluid leading 
respiratory distress, severe gastrointestinal involvement such as persistent vomiting, 
and severe organ impairment including acute liver failure and acute renal failure14,35. 
DEN patient is considered to have shock when the differences between the systolic and 
diastolic pressure is ≤20 mm Hg or has cold extremities, delayed capillary refill or rapid 
pulse rate. Platelets counts lower than 50,000 cells/mm3 are considered sign of severe 
disease27. In 2009 WHO DEN case classification listed symptoms such as severe 
plasma leakage, severe hemorrhage, and severe organ impairment including 
myocarditis, hepatitis, and encephalitis as criteria for severe dengue14,23,39.  
 
1.6. Dengue diagnosis 
DEN diagnostics detects either the viral components (genome or antigen) or the host 
response to the virus (serology testing) or both14,35.  
 
1.6.1. Detection of viral components 
In early stage of infection, virus isolation, nucleic acid or antigen detection are 
used for DEN diagnosis. DENV can be detected in serum, plasma, circulating blood 
cells and tissues on days 4-5 after the onset of illness27. Reverse-transcriptase 
polymerase chain reaction (RT-PCR), quantitative RT-PCR (qRT-PCR) and isothermal 
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RNA amplification assay are used to detect the viral genome components in serum and 
plasma. In contrast, enzyme-linked immunosorbent assay (ELISA) are used to detect 
virus-expressed soluble non-structural protein-1 (NS1)35. Virus isolation is a cell 
culture technique that used mosquitoes cell line (C6/36) or mammalian cell lines (Vero, 
LLCMK2 and BHK21) as host cell to isolate DENV.  
 
1.6.2. Detection of host response 
Serology method is usually used to diagnosis DEN at the end of acute DEN 
phase27. ELISA assay is used to determine the presence of DENV-specific IgM or IgG 
antibody. In primary DEN infection, IgM antibody detected earlier than IgG antibody. 
In secondary DEN infection, IgG antibody detected earlier than IgM antibody. The 
IgM/IgG antibody ratio is used to distinguish between primary and secondary DENV 
infection.  
 
1.6.3. Plaque reduction neutralization test  
Plaque reduction neutralization test (PRNT) is a gold-standard technique to 
measure the titer of neutralizing antibodies in the serum. Neutralization assay detects 
and quantifies neutralizing antibodies in serum samples by calculating the percentage 
of reduction of virus activity, as the concentration of virus used is usually constant40. 
The PRNT and the micro-neutralization assay served as method to determine the 
protection levels by using levels of neutralizing antibodies  as a proxy of protection41. 
These techniques are mainly used in vaccine development studies to determine the 
vaccine efficacy and safety.  
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1.7. Dengue pathogenesis 
DEN is multifactorial disease that involved several factors including viral factors, 
cytokines storms/soluble factors, host genetic factors, transient autoimmunity, cross-
reactive T- cell response, and antibody-dependent enhancement5,11,37,42. Because of the 
complexity of the DEN pathogenesis, one had to consider all the immunological, 
pathological, clinical and epidemiological features to understand DEN pathogenesis.  
 
1.7.1. Viral factors 
DENV are genetically diverse and classified into distinct genotypes with different 
geographical distribution and pathogenic potential11,43. Antigenic differences among 
genotypes and serotypes of DENV were associated with disease severity, epidemic 
cycling and viral evolution20. Certain strains and genotypes of DENV are able to induce 
high levels of viremia and associated with severe disease16,18,37. Primary DENV-1 
infection is associated with overt cases while primary DENV-2 and DENV-3 infection 
are mostly asymptomatic44. Secondary DENV-2 infection is associated with severe 
disease with signs of plasma leakage44–46. Patient infected with DENV-4 usually has 
milder clinical profile46. 
 
1.7.2. Antibody-dependent enhancement 
In most acute virus infection models, neutralizing and non-neutralizing antibodies 
correlates with control, elimination and protection of the host cells37. DENV infection 
with one serotype will induce long-lasting protection against homologous serotype. 
However, cross-reactive protection against other DENV serotypes wanes after few 
months5. However in DEN infection, DENV sub-neutralizing, infection-enhancing 
antibodies induced during primary infection was risk factor for disease severity in 
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secondary infection with heterologous serotype47,48. Antibody-dependent enhancement 
(ADE) theory is based on the observations that pre-flavivirus immune individual had 
higher risk to develop for severe disease during secondary infection because non-
neutralizing cross-reacting antibody facilitated virus entry into the cells via Fc gamma 
(Fc receptor, in turn, enhance viral infection, and lead to increase in viral load7,49.  
 
1.8. Immune responses during dengue virus infection  
Virus can either directly or indirectly cause illness. In direct mechanism, cytopathic 
effect cause by the virus infection of the cells leads to organ malfunctions and illness50. 
In contrast, in indirect mechanism, organs malfunctions and illness may have been 
caused by immune responses to the virus50. The innate responses and adaptive cellular 
immune responses facilitate recovery from virus infection and confer protection against 
homologous infection. However, immune response could also cause disease 
(immunopathogenesis)50,51.  
 
1.8.1. Humoral immunity 
Humoral immune response is mediated by antibody molecules that are secreted 
by plasma cells52. In humoral immunity, virus or virus-infected cell stimulated B 
lymphocytes to induce antibody. When the antigen binds to the immunoglobulin 
receptor at cell surface, B cell will interact with macrophages and helper T lymphocytes, 
and B cell will then differentiate into clones of antibody-secreting plasma cells. This 
cells than secreting antigen-specific immunoglobulin (IgG) of one five major classes: 
IgA, IgD, IgE, IgM, and IgG antibody. The IgA, IgM, and IgG antibody have antiviral 
properties53. IgG antibody is responsible for the most antiviral activity in serum. 
Interestingly, IgG antibody also plays an important role in disease enhancement10. 
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1.8.2. Cell-mediated immunity 
Cell-mediated immunity refers to identification and/or elimination of virus or 
virus-infected cell by leukocytes, and production of different soluble factors 
(cytokines) by cells when induced by virus or virus-infected cell53. Cell-mediated 
immunity involves T lymphocytes, antibody-dependent cell-mediated cytotoxicity 
(ADCC), macrophages, natural killer (NK) cells, lymphokines, and monokines to 
respond for viral infection.  
 
1.8.3. Innate responses 
Innate responses refer to those that neither require previous antigenic exposure 
nor show enhanced response during subsequent exposure (memory). Innate responses 
provide the host the time that needed to induce adaptive immunity. Innate immune 
responses including interferons (IFNs) and NK cells that are rapidly activated after viral 
infection. Dendritic cells (DC), NK cells, and natural killer T (NKT) cells participate 
in innate immune responses during DENV infection.  
 
1.8.4. Adaptive responses 
In contrast, adaptive immune responses are develop upon exposure to pathogens 
and respond in an antigen-specific manner upon further exposure; these include T 
lymphocytes, and B lymphocytes and their associated antibodies37,54. During primary 
infection, the adaptive immune responses follow the innate immune responses in time. 
The naïve T lymphocytes activation require antigen that are expressed by the 
specialized antigen-presenting cells including macrophages, B lymphocytes, or 
dendritic cells. After the elimination, T lymphocytes are converted into a “memory” 
phenotypes for more rapid activation and response upon re-exposure54. During 
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secondary infection, T-cell responses are rapidly induced, and antibodies levels are 
increased earlier following infection. Although, adaptive immune responses are 
important to prevent re-infect, these responses are also the risk factors for disease 
severity because of the enhancement properties and the strong association between 
severe DEN case and preexisting neutralizing antibodies39. In addition of that, severe 
DEN case was proposed to be caused by immune-mediated than viral mediated because 
severe DEN was developed after the clearance of viremia.55. 
 
1.8.5. Antibody response 
Antibody is the products of adaptive humoral immune response56. During primary 
infection, Immunoglobulin M (IgM) antibody responses earlier to DEN antigen 
followed by IgG antibody. IgM antibody is detectable on 3rd afebrile day after 
defervescence in clinically apparent case while IgG antibody is detectable during 
convalescent phase.  IgM antibody persists for 1-2 months after the infection57. In 
contrast, during secondary infection, IgG antibody respond earlier than IgM antibody. 
In DENV infection, IgM antibody predominantly respond to E protein, but  response to 
NS proteins are also detected57. In convalescent phase during primary infection, IgG 
antibody predominantly respond to prM and E proteins. However, following primary 
and secondary heterologous infection, IgG antibody response to C, NS1, ND3, and NS5 
proteins are also detected58–60. 
 
1.8.6. Neutralizing antibodies 
Neutralizing antibodies play a central role in protection against DENV infection 
and disease pathogenesis. Neutralizing antibodies neutralized the virus either by 
blocking the attachment of the virus to the cells or blocking a post-attachment step in 
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the entry process53. Virus neutralization occurs when antibody binds to the 
complementary epitopes on the virus surface, and the numbers of antibody bound to the 
virions exceed critical threshold preventing the virus binding to target cells 56–58. E and 
pre-M proteins are the principal target of antibody responses2. A majority of 
neutralizing antibodies response against E protein are thought to be cross-reactive 
among serotypes because DENV serotypes are antigenically related2,63. Nonetheless, 
serotype-specific neutralizing antibodies are also induced after DENV infection, and 
these antibodies were highly genotype-specific and antigen differences among 
genotypes and serotypes of DENV affected the abilities of neutralizing antibodies to 
offer protection6. The fundamental assumption that neutralizing antibodies induced 
during DENV infection confers protection against re-infection with homologous 
serotype of DENV were challenged when incidence of incomplete protection during 
heterologous genotype infection were reported13,14,64,65. Forshey et. al (2016) reported 
that during outbreak of DENV-2 Asian/American genotype in Peru, that neutralizing 
antibodies induced during previous outbreak of DENV-2 American genotype did not 
confer protection against infection with DENV-2 Asian/American genotype13. The 
incomplete protection against heterologous genotype may have been caused by the 
antigenic differences among genotypes. Antigenic differences cause the structural 
change on viral proteins that will modify the antibody binding site, and certain 
antibodies did not able to interact with epitopes in EDIII domain belonging to E protein 
of different genotypes within the same3,12.   
1.9. Dengue vaccine 
The development of DEN vaccine has been hampered by antigenic and genetic 
differences of the virus, lack of cross-reactive immunity among genotypes/serotypes of 
DENV, and the host immune response3. In 2016, CYD-TVD become the first 
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commercially available DEN vaccine66–69. In addition of that, there are currently five 
candidate vaccines in human clinical trial phase including DENVax, TV003/TV005, 
TDENV PIV, V180 and D1ME10070. 
 
CYD-TVD (Dengvaxia) is DEN vaccine that was developed by Sanofi Pasteur and 
was licensed to be use in 19 countries including DEN-endemic countries66–69. 
Dengvaxia is a tetravalent live-attenuated chimeric DENV vaccine based on the yellow 
fever (YF) 17D vaccine strain70. This tetravalent DEN vaccine was constructed by 
replacing the prM and E proteins of YF vaccine strain with those prM and E proteins 
of the four DENV serotypes70,71. Although Dengvaxia could reduce DEN-related 
hospital admission by 10-30% over the next 30 year, the efficacy of the vaccine against 
all DENV serotype was only 44.6-65.6% 67,72,73. The efficacy against DENV-2 was only 
33.6-47.1% and the lowest among other serotypes72. In 2016, WHO Strategic Advisory 
Group of Experts (SAGE) reported that Dengvaxia was safe to be used in DEN endemic 
regions and in targeted age group of people aged 9-45 years33,66. Nonetheless, Aguiar 
et. al (2016) suggested that Dengvaxia should only be given to DEN seropositive 
individual and immunological screening should be done prior to vaccination67,68,74. 
Several concerns were raised about the administration of Dengvaxia without the 
identification of the immune status at the time of vaccination as Dengvaxia increased 
the risk dengue-related admission in DEN seronegative individual67,68,75. In 2017, 
Sanofi acknowledged the differences in Dengvaxia performance based on prior DEN 
infection69.  
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1.10. Animal model of dengue virus infection 
Animal model of DENV infection was used in dengue tropism and pathogenesis 
studies, dengue immunopathogenesis studies, development of the immune response 
studies, therapeutics testing and vaccine evaluation studies36,76,77. Development of 
reliable animal model that can better reflect the DENV infection in human will allow a 
better understanding on the DENV pathogenesis topics. A good animal model of DENV 
infection should be able to demonstrate high sensitivity to DENV, induce high levels 
of DENV replication and exhibit disease sign upon DENV inoculation. However, due 
to the complexity of DENV, it was difficult to find a good animal models of DENV 
infection that better reflect and mimicking DENV infection in humans. 
 
1.10.1. Mouse model 
The wild-type mice,  human tissue engrafted-SCID, interferon alpha, beta, gamma 
deficient AG129, RAG-hu, and the NOD/SCID/IL-2R/human CD34 transplant or 
immunized mice are the breeds that had been used as animal model of DENV 
infection55,76. Initial mouse models of DEN demonstrated low-levels of virus 
replication upon inoculation with clinically isolated DENV. The neurotropic disease 
and splenomegaly symptoms that were observed in AG129 mouse and paralysis 
symptom that were observed in engrafted-SCID mouse did not faithfully reflect the 
clinical signs of DENV infection in human55,76. Nonetheless, the AG129 mice was a 
reliable model to study the role of NS1 antigen and anti-NSI antibody due to high levels 
of circulating NS1 antigen and anti-NS1 antibody during DENV infection76. In addition 
of that, AG129 mouse model had been utilized in therapeutics testing because these 
mice developed disease features resembling human dengue disease76. 
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1.10.2. Non-human primate model 
Non-human primate (NHP) is reliable animal model of DENV infection because of 
the similarities in genetic proximity between the NHP and human. NHP had been used 
as animal model in dengue tropism and pathogenesis studies, immunopathogenesis 
studies, and vaccine development studies 78–82. Detection of  DENV antibodies in sera 
of wild NHP indicated that NHP were involved in DEN transmission in sylvatic cycle77. 
NHP was able to sustain viral replication after inoculation with 104-106 PFU of DENV 
(mimic the inoculum in a mosquito bite) via subcutaneous inoculation76. NHP also 
developed antibody responses similar to those in humans78. Nonetheless, the viral 
replication in some NHPs including pigtail macaques, rhesus macaques, and owl 
monkeys were lower than those in humans76,77,83–86. Some rhesus macaques displayed 
low platelet count and lack of clinical disease signs36,76,80. In recent years, rhesus 
macaques demonstrated hemorrhagic manifestations when inoculated with higher dose 
of DENV via intravenous route80.  
 
1.10.3. Common marmoset 
 Common marmoset (Callithrix jacchus) is small New World monkey36. 
Common marmoset inhabits mainly in South America. Common marmoset was used 
as an experimental animal model in drug toxicology studies, neurosciences studies, 
autoimmune diseases studies, and infectious diseases studies87. Common marmoset was 
a good infection model for DENV because marmoset constantly developed high levels 
of viremia upon inoculation with clinically-isolated DENV36,83. Common marmoset 
also demonstrated antibody response patterns that were consistent with those in human 
DENV infections and candidate vaccines recipients83,88.  
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1.11. Research purpose and objectives 
 
DENV-2 is the most prevalent DENV serotype in worldwide epidemic. 
Neutralizing antibodies play an important role in protection against DENV infection. 
Current tetravalent DEN vaccine against all four serotypes of DENV was developed 
using only single genotype from each serotype of DENV, with assumption that 
infection with one genotype of a serotype will confer protection against all genotypes 
within the same serotype. It is widely believed that, despite the antigenic differences, 
strain variation within serotype does not affect the ability of neutralizing antibodies to 
offer protection. Nonetheless, the efficacy of DENV-2 vaccine was only 33.6-47.1% 
and the lowest among four serotypes. It was speculated that antigenic differences lead 
to structural change on viral protein that will modify the antibody binding site and affect 
the ability of neutralizing antibodies to neutralize heterologous genotype. Studies on 
the levels of neutralizing antibodies to different genotypes of DENV-2 have been 
limited. In addition of that, studies on correlation between antigenic differences in 
genotype and levels of viremia and cell-mediated immunity have been limited as well.   
 Thus, the present study aims to: 
i. Determine levels of genotype-specific and genotype cross-reactive neutralizing 
antibody in response to DENV-2 in primary, secondary and tertiary DENV 
infections in common marmosets (Callithrix jacchus) model. 
ii. Determine levels of viremia and immune-related gene in primary, secondary and 
tertiary DENV infections in common marmosets (Callithrix jacchus) model. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Virus 
Three strains of DENV-1 were used in this study (Figure 1). Phylogenetic tree was 
constructed by using nucleotide sequence of the complete E protein region and obtained 
using Neighbor-joining (NJ) method in MEGA software89. DENV-1 Yoyogi-Tokyo 
strain (GenBank accession no. LC006123) was isolated from dengue fever (DF) case 
from Tokyo 2014 outbreak, and belongs to the genotype I (GI) genotype. DENV-1 
16007 strain (GenBank accession no. AF180817) was isolated from dengue 
hemorrhagic fever (DHF) case, and belongs to the genotype II (GII) genotype. DENV-
1 02-17 strain (GenBank accession no. AB111075) was isolated from imported DF case 
from Indonesia, and belongs to the genotype IV (GIV) genotype.  
 
Four strains of DENV-2 were used in this study (Figure 2). Phylogenetic tree was 
constructed by using the nucleotide sequence of the complete E protein region and 
obtained using NJ method in MEGA software as well89. DENV-2 DHF0663 strain 
(GenBank accession no. AB189122) was isolated from imported DHF case from 
Indonesia, and belongs to the Cosmopolitan genotype. DENV-2 00-43 strain (GenBank 
accession no. AB111452) was isolated from imported DF case from Indonesia, and 
belongs to the Asian I genotype. DENV-2 16881 strain (GenBank accession no. 
M84727) was isolated from DHF case, and belongs to the Asian I genotype. DENV-2 
08-77 strain (GenBank accession no. AB545874) was isolated from imported DF case 
from Maldives, and belongs to the Asian/American genotype.  
 
All the DENV strains were first isolated using C6/36 cells, and passaged in baby 
hamster kidney (BHK) cells. Culture supernatants collected from infected BHK cells 
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were centrifuged at 3000 rpm for 5 minutes to remove cell debris. Virus stocks were 
used within four cell culture passages. Virus stock was stored at -80℃ before use.  
 
2.2. Candidate vaccine strain 
DENV-1 16007 PDK-13 vaccine strain is a monovalent live attenuated DENV-
1 vaccine candidate that was attenuated by serial passage in primary dog kidney (PDK) 
cells (GenBank accession no. AF180818). DENV-2 16881 PDK-53 vaccine strain is a 
monovalent live attenuated DENV-2 vaccine candidate that was attenuated by serial 
passages in PDK cells (GenBank accession no. M84728). All the vaccine strains were 
prepared by Professor Sutee Yoksan at Institute of Molecular Biosciences, Mahidol 
University, Nakhon Pathom, Thailand, shipped in liquid form on dry ice to National 
Institute of Infectious Diseases, Tokyo, Japan, and stored at –80 °C before use. 
 
2.3. Samples collected from marmosets 
Common marmosets (Callithrix jacchus) were obtained from CLEA Japan, Inc. 
(Tokyo, Japan) and maintained in specific pathogen-free conditions at the National 
Institute of Infectious Diseases (Tokyo, Japan).  
 
2.3.1 Study on the levels of genotype-specific and genotype cross-reactive 
neutralizing antibodies to DENV-2 genotype 
A total of 59 blood samples were collected from 34 marmosets in the study. In 
groups 1-12, 43 plasma samples were collected from 26 marmosets with primary 
(N=28), secondary (N=12), and tertiary (N=3) DENV infection (Table 1). In group 1-
12, the marmosets were inoculated subcutaneously with 106 plaque forming unit (pfu) 
dose-1 of DENV. The interval between each of DENV inoculation was about 4-12 
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months (based on vaccine administration schedule). In groups 13-17, 16 blood samples 
were collected from eight marmosets that were inoculated with monovalent live-
attenuated DEN vaccine candidates: DENV-1 16007 PDK-13 strain and DENV-2 
16881 PDK-53 strain. In groups 15-16, marmosets received 104 pfu dose-1 of DENV-1 
and DENV-2 vaccine strains, and about 6-9 months after the first administration, the 
marmosets were inoculated with 105 pfu dose-1 of DENV-1 or DENV-2. A total of 1 
mL of whole blood was collected in EDTA tubes from each marmoset on day 0 (before 
the virus inoculation), and on days 4, 7, and 14 post-inoculation (p.i.). Next, the blood 
samples were centrifuged at 2000 rpm for 10 minutes at 4℃. Plasma samples were 
stored at -80℃ before use. We determined the presence of DENV-specific IgM 
antibody in all the marmosets in each group to indicate whether the DENV infection 
was established (Figure 3). Levels of DENV-specific IgM antibody in groups 1, 2, 3, 4, 
5, 6, 11, 12, 13, 14, 15, 16, and 17 marmosets were above the baseline detection levels. 
Levels of DENV-specific IgM antibody in groups 7-10 marmosets were below the 
baseline detection levels.  
 
2.3.2 Study on the levels of viremia and immune-related gene 
A total of 19 plasma samples were collected from 7 groups of marmosets with 
primary (N=6), secondary (N=7), and tertiary (N=6) DENV infection (Table 2). There 
were 2 groups of primary infection marmosets, 3 groups of secondary infection 
marmosets, and 2 groups of tertiary infection marmosets. Group A consists of 
marmosets that were inoculated with DENV-2 Asian I genotype and group B consists 
of marmosets that were inoculated with DENV-2 Asian/American genotype. Group C 
and group D marmosets consist of marmosets that were inoculated with homologous 
serotype in secondary infection, while group E marmosets consists of marmosets that 
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were inoculated with heterologous serotype in secondary infection. Group F consists of 
marmoset that were inoculated with DENV-2 Asian I genotype in primary infection, 
DENV-2 Cosmopolitan genotype in secondary infection and DENV-1 GI genotype in 
tertiary infection, and group G consists of marmosets that were inoculated with DENV-
2 Asian I genotype in primary infection, DENV-2 Cosmopolitan genotype in secondary 
infection and DENV-1 GIV genotype in tertiary infection. All the marmosets were 
inoculated with 106 pfu/DENV. The interval between each DENV inoculation was 
about 4-12 months. A total of 1 mL of whole blood was collected in EDTA tubes from 
each marmoset on day 0 (before the virus inoculation), and on days 2, 4, 7, 10, and 14 
p.i. Next, the blood samples were centrifuge at 2000 rpm for 10 minutes at 4C to collect 
plasma. Plasma samples were stored at -80C before use. 
 
2.4. Determination of neutralizing antibodies titers using plaque reduction 
neutralization test assay  
Neutralizing antibodies titers to DENV-2 Cosmopolitan, Asian I, and 
Asian/American genotypes were determined using plaque reduction neutralization test 
assay (PRNT). BHK cells were seeded in 12-wells plate in Minimum Essential Medium 
(MEM) (Sigma Aldrich) containing 10% of heat-inactivated fetal bovine serum (Hi-
FBS) (Gibco), and incubated at 37℃ overnight until 70% confluency was reached. 
Plasma samples were heat-inactivated at 56℃ for 30 minutes before use. Heat-
inactivated plasma samples were serially diluted two-fold starting from 1:10 to 1:20480 
in MEM containing 10% Hi-FBS. Virus-antibody complexes were prepared by mixing 
25 μL of DENV at titers of 5000 pfu ml-1 with 25 μL serially diluted plasma samples 
to make final dilution series ranging from of 1:20 to 1:40960. Control samples were 
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prepared by mixing 25 μL of DENV at titers of 5000 pfu ml-1 with 25 μL MEM 
containing 10% Hi-FBS. Next, the virus-antibody complexes were incubated at 37℃ 
for 60 minutes. Next, a total of 50 μL of the virus-antibody complexes mixture were 
inoculated onto BHK cell monolayer in 12-wells plate. After incubation for 60 minutes, 
1ml of maintenance medium containing MEM, 1% of methyl cellulose, and 2% of Hi-
FBS was added. Plate was incubated at 37℃ in 5% CO2 until visible plaques were 
observed (5-7 days of incubation). Plaques were fixed with 10% formaldehyde and 
stained with methylene blue, washed with water, and then counted. All tests were 
conducted in duplicate. Neutralizing antibodies titer was expressed as the maximum 
dilution of plasma sample that yielded a ≥50% plaque reduction in the virus inoculum 
compared with control virus sample. Results are shown as 50% PRNT50 values, 
expressed as reciprocal of the highest plasma dilution (end-point titer) that results in 
≤50% of the input plaque count. 
 
2.5. Determination of DENV-specific IgM and IgG antibodies 
Presence of DENV-specific IgM antibody was determined using Focus Dengue 
Fever IgM capture ELISA kit (Focus Diagnostic). Presence of DENV-specific IgG 
antibody was determined using Panbio Dengue IgG Indirect ELISA kit (Alere). Plasma 
samples from three DENV-naïve marmosets were used as negative control. Ratio 
positive (P): negative (N), P: N≥2 were considered positive. Ratio P: N was calculated 
using the formula: absorbance of the test sample/absorbance of the negative control. 
All ELISAs were conducted in duplicate. 
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2.6. Determination of NS1 antigen 
Presence of NS1 antigen were determined using PlateliaTM Dengue NS1 Ag-
ELISA kit (Biorad Laboratories). Plasma samples collected from 3 DENV-naïve 
marmosets were used as negative control. Ratio P: N≥2 were considered positive. All 
ELISAs were conducted in duplicate. 
 
2.7. Isolation of viral RNA 
Viral RNA (vRNA) of DENV was isolated from plasma by using High Pure Viral 
RNA kit (Roche Diagnostic) according to the manufacturer’s instructions to a final 
volume of 50l per sample.  
 
2.8. Determination of viral RNA copy numbers 
vRNA copy numbers were determined using quantitative Taqman real-time reverse 
transcriptase polymerase chain reaction (qRT-PCR) 90. Result of vRNA copy numbers 
was expressed as log10 genome copies per milliliter. 
 
2.9. Determination of DENV titers using plaque assay 
BHK cells were seeded in 12-wells plate in MEM containing 10% of Hi-FBS, and 
incubated at 37C overnight until 70% confluency was reached. Plasma samples were 
serially diluted 10-fold from 1:10 to 1:106. A total of 50 µL of the diluted plasma was 
inoculated onto BHK cells monolayer. After incubation for 60 minutes, 1 mL of 
maintenance medium containing MEM, 1% of methyl cellulose and 2% of Hi-FBS was 
added. Plate was incubated at 37C in 5% CO2 until visible plaques were observed (5-
7 days of incubation). Plaques were fixed with 10% formaldehyde, stained with 
methylene blue, washed with water, and then counted. All tests were conducted in 
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duplicate. Viral titers were expressed as plaque forming unit per millimeter (pfu mL-1) 
using the following formula: (average number of plaques x dilution)/inoculum volume.  
 
2.10. Isolation of RNA from leukocytes 
A total of 0.5 mL of whole blood was added into 10 mL of ammonium chloride 
(NH4Cl) solution to lyse the red blood cells. Blood samples were centrifuged at 2700 
rpm for 3 minutes at 4C and supernatant was discarded. Pellet was washed with 10 mL 
of Hank’s Balanced Salt Solution (HBSS), vortexed, and centrifuged at 2700 rpm for 3 
minutes at 4C, and supernatant was discarded. Next, pellet was dissolved by repeat 
pipetting, transferred into 1.5 mL of centrifuge tube, centrifuged at 4000 rpm for 1 min 
and supernatant was discarded. Leukocytes were lysed with QIAzol Lysis reagent 
(Qiagen, Germany). Total RNA was extracted using Direct-zol RNA MiniPrep kit 
(Zymo research, USA) according to manufacturer’s instructions.  
 
2.11. Determination of levels of immune-related gene 
Levels of GAPDH, CD3, CD4, CD8IFN-, IL-1, IL-2, and IL-10 on days 0, 
2, 4, 7, 10, and 14 p.i. were determined using qRT-PCR87. The first-strand of cDNA 
was synthesized using PrimeScript® RT reagent kit (Takara, Japan) with attached 
random hexamers and oligo (dT) primers. Reaction was incubated at 37ºC for 15 mins 
followed by 85ºC for 5 seconds according to the manufacturers’ instructions. Levels of 
immune-related genes were quantitated by qRT-PCR using Applied Biosystems 
QuanStudio® 5 system. PCR reaction consisted of 10 μL of Thunderbird® SYBR® 
qPCR mix, 2μL of 5μM primer mix, 0.4μL of 50X ROX references dye in a total 
volume of 20μL. The cycling conditions were as follows: 30 secs at 95ºC followed by 
40 rounds of 95ºC for 15 secs and 60ºC for 30 secs. Melting curve analysis to determine 
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the dissociation of PCR product was performed between 65ºC and 95ºC. The qRT-PCR 
data were analyzed using comparative Ct method and normalized using GAPDH level 
as a reference gene91. Data were expressed as mean values of 2-∆∆Ct.  
 
2.12. Data analysis 
Data were analyzed using the statistical analysis toolpack in Microsoft Excel 2016 
(Microsoft Corporation) and GraphPad Prism 7 (GraphPad Software Inc.). Student’s t-
test analysis was used to determine the differences between neutralizing antibodies 
titers between genotypes and differences between levels of immune-related genes on 
days 2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a 
reference. Probability values (p) less than 0.05 (p<0.05) were considered significant. 
 
2.13. Ethics statement 
These animal studies were conducted with accordance with the guidelines of the 
Institutional Animal Care and Use Committee of the National Institute of Infectious 
Diseases (NIID), Tokyo, Japan. This study was approved by the Institutional Animal 
Care and Use Committee of NIID (approval no.613006 and 516010). All animals and 
infection experiments were performed according to the NIID Institutional Guidelines, 
in additions to the guidelines of the Science Council, and local rules and regulations.
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2.14. Tables and Figures 
Table 1. List of marmosets that were used in study on levels of genotype specific and genotype cross-reactive neutralizing antibodies. 
Type of infection Primary infection Secondary infection Tertiary infection  Intervals between 
DENV infection 
Marmosets ID 
Serotype (Genotype)  Serotype (Genotype) Serotype (Genotype)  
Primary infection 
Group 1 D1 (GI)    M1, M2 
Group 2 D1 (GII)    M3-1, M4-1, M5-1, M6,  
Group 3 D2 (Cosmopolitan)    M7-1, M8-1, M9-1, M10, 
M11, M12, M13, M14 
Group 4 D2 (Asian I)    M15-1, M16-1, M17-1,  
M18-1, M19-1, M20-1 
Group 5 D2 (Asian/American)    M21, M22, M23 
Secondary infection     
Homologous genotype 
Group 6 
Group 7 
Group 8 
 
 
D2 (Cosmopolitan) 
D2 (Asian I) 
D2 (Asian American) 
 
D2 (Cosmopolitan) 
D2 (Asian) 
D2 (Asian/American) 
  
6 months 
4 months 
4 months 
 
M24, M25 
M18-2, M19-2 
M21-2, M22-2, M23-2 
Heterologous genotype 
Group 9 
 
D2 (Asian I) 
 
D2 (Cosmopolitan)  
  
6 months 
 
M15-2, M16-2, M17-2, M26 
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Type of infection Primary infection Secondary infection Tertiary infection Intervals between 
DENV infection 
Marmosets ID 
Serotype (Genotype) Serotype (Genotype) Serotype (Genotype) 
Homologous serotype 
Group 10 
Heterologous serotype 
Group 11 
 
D1 (GII) 
 
D2 (Cosmopolitan) 
 
D1 (GI) 
 
D1 (GI) 
  
7 months 
 
12 months 
 
M3-2, M4-2, M5-2 
 
M7-2, M8-2, M9-2 
Tertiary infection 
Group 12 
 
D2 16881 (Asian I) 
 
D2 (Cosmopolitan) 
 
D1 (GI) 
 
12 months 
 
M15-3, M16-3, M17-3 
Primary infection with monovalent live-attenuated DEN vaccine candidate    
Group 13 
Group 14 
D1 16007 PDK-13 (GII) 
D2 16881 PDK-53 (Asian I) 
   V1-1, V2-1, V3-1, V4-1 
V5-1, V6-1 
Secondary infection     
Group 15 
Group 16 
D1 16007 PDK-13 (GII) 
D2 16881 PDK-53 (Asian I) 
D1 (GI) 
D2 (Cosmopolitan) 
 7 months 
6 months 
V1-2, V2-2, V3-2, V4-2 
V5-2, V6-2, V7-1, V8 
Tertiary infection 
Group 17 
 
D2 16881 PDK-53 (Asian I) 
 
D2 (Cosmopolitan) 
 
D1 (GI) 
 
12 months 
 
V5-3, V7-2 
D1=DENV-1, D2= DENV-2, D3= DENV-3, D4= DENV-4 
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Table 2. List of marmosets that were used in study on levels of viremia and immune-related genes. 
Type of infection Primary infection  Secondary infection Tertiary infection Marmoset ID 
Serotype Genotype Serotype Genotype  Serotype Genotype 
Primary infection 
Group A 
Group B 
 
D2 
 
Asian I 
     
A1, A2, A3 
 Asian/American     B1, B2, B3,  
 Secondary infection 
Homologous serotype 
Group C 
Group D 
 
Heterologous serotype 
Group E 
 
D2 
 
 
Asian I 
Asian/American 
 
D2 
 
Asian I 
Asian/American 
   
C1, C2 
D1, D2, D3  
 
 
D2 
 
 
Cosmopolitan 
 
 
D1 
 
 
GI 
   
 
E1, E2 
Tertiary infection 
Group F 
Group G 
 
D2 
D2 
 
Asian I 
Asian I 
 
D2 
D2 
 
Cosmopolitan 
Cosmopolitan 
 
D1 
D1 
 
GI 
GIV 
 
F1, F2 
G1, G2, G3, G4 
D1=DENV-1, D2= DENV-2, D3= DENV-3, D4= DENV-4 
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Figure 1. Phylogenetic tree of the DENV-1 strains that were used in this study. 
Closed arrowhead indicates virus strains that were used in this study, DENV-1 Tokyo-
Yoyogi strain belongs to GI genotype, DENV-1 16007 strain and DENV-1 16007 PDK-
13 vaccine strain belong to GII genotype, and DENV-1 02-17 strain belongs to GIV 
genotype. 
 
 
GV 
GI 
GIII sylvatic 
GII 
GIV 
 AF311956 Brazil 1997
 KM279416 Mexico 2012
 AF425631 Trinidad and Tobago 1978
 AB111065 Japan (99-36) 1999
 AB111071 Cambodia 2001
 JQ403518 Taiwan 2008
 AB111064 Japan (98-35-1) 1998
 AB915378 Indonesia 2013
 GQ357670 Singapore 2008
 KJ806821 Malaysia 2013
 KJ545459 Guangzhou 2013
 LC006123 Tokyo 2014
 LC002828 Saitama 2014
 AF425630 PUO356 Thailand
 AF425622 Malaysia 1972
 D10513 Thailand 1954
 AF425629 Thailand 1963
 AF180817 16007
 AF180818 16007 PDK13
 DQ285553 Reunion 2004
 EU448411 Indonesia 2010
 EU448412 Madagascar 2006
 AB111070 Japan (01-44) 2001
 AB189120 Indonesia 1998
 KM216687 Indonesia 2010
 JF459993 Myammar 2002
 AB111075 Japan (02-17) 2002
 AY422784 Philippines 1995
 D00502 Thailand 1980
 D00501 Carribean 1977
 AB214879 Japan DENV-3
 AB189123 Japan DENV-2
 AB111088 Japan DENV-4
95
100
100
100
100
100
99
100
100
99
100 99
100
95
100
99
100
0.05
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Figure 2. Phylogenetic tree of the DENV-2 strains that were used in this study. 
Closed arrowhead indicates virus strains that were used in this study. DENV-2 
DHF0663 strain belongs to Cosmopolitan genotype. DENV-2 16881 strain, DENV-2 
16881 PDK-53 vaccine strain, and DENV-2 00-43 strain belong to Asian I genotype. 
DENV-2 08-77 strain belongs to Asian/American genotype. 
Cosmopolitan 
Asian I 
Asian II 
Asian/American 
American 
 AB111449 Japan-India (96-19) 1996
 AB194883 Japan-Sri Lanka (04-23)
 AF410379 Singapore 1991
 AF231715 Malaysia 1969
 AF004019 Australia 1997
 AF004020 Cook Island 1997
 AB111450 Japan-East Timor (00-09) 2000
 AY037116 Australia 1993
 JN030268 Singapore 2009
 AB219135 DENV-2 TLC30
 AB111451 Japan-Philippines (00-36) 2000
 AB189122 Japan-Indonesia (DHF0663) 1998
 AB189123 Japan (98900665 DF) 1998 DENV-2
 AB189124 Japan (98900666 DSS) 1998 DENV-2
 M84728 16681-PDK53
 M84727 D2 16681 Thailand
 AF022434 Thailand 1993
 AF469176 China 1998
 AF100464 Thailand 1980
 AB111452 Japan-Sri Lanka (00-43) 2000
 M24445 Thailand 1989
 X15433 Malaysia 1987
 AF195039 Thailand 1999
 AF264053 Thailand 1980
 D00345 D2 PUO218
 AF204178 China 1987
 M24450 Sri Lanka 1968
 AF119661 China 2004
 AF410359 Vietnam 1998
 AF195040 Thailand 1991
 AF195043 Thailand 1983
 AB545873 Japan-Jamaica (07-77)
 AB545874 Japan-Maldives (08-77)
 AF208496 Martinique 1998
 M15075 Jamaica 1983
 X54319 Tonga 74
 AY158328 Venezuela 1987
 AF264054 Puetro Rico 1969
 L10046 Puerto Rico 1969
 AB111088 Japan (02-12-1) 2002 DENV-4
 AB214879 Japan (TL018) 2005 DENV-3
 LC006123 Japan (Tokyo) 2014 DENV-1
100
100
100
100
100
100
100
100
0.05
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Figure 3. Levels of DENV-specific IgM antibody in plasma samples of group 1-17 
marmosets on days 0, 4, 7, and 14 p.i. Dash line indicates baseline of the positive 
value for P:N ratio. Day 0 was defined as virus inoculation day. 
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CHAPTER 3: RESULTS 
3.1. Levels of neutralizing antibodies 
3.1.1 Levels of neutralizing antibodies to genotypes of DENV-2 following primary 
DENV-1 and DENV-2 infection 
Five groups of marmosets were used in the study to determine levels of 
genotype-specific and genotype cross-reactive neutralizing antibodies to DENV-2 
Cosmopolitan, Asian I, and Asian/American genotypes following primary DENV-1 
and DENV-2 infections. Group 1 and group 2 consisted of marmosets that were 
inoculated with DENV-1 GI and DENV-1 GII genotypes, respectively. Group 3, group 
4, and group 5 consisted of marmosets that were inoculated with DENV-2 
Cosmopolitan, DENV-2 Asian I, and DENV-2 Asian/American genotypes, 
respectively.   
 
Following primary DENV-2 infection, neutralizing antibodies to all three 
genotypes of DENV-2 (Cosmopolitan, Asian I and Asian/America genotypes) were 
absent in group 3, group 4, and group 5 marmosets from days 0-7 p.i. (Figure 4a-c). 
Neutralizing antibodies to Cosmopolitan, Asian I, and Asian/American genotypes were 
detected in group 3, group 4, and group 5 marmosets on day 14 p.i. (Figure 4a-c). In 
Group 3 marmosets, the levels of genotype cross-reactive neutralizing antibodies to 
Asian I genotype were significantly higher than the levels of genotype-specific 
neutralizing antibodies to Cosmopolitan genotype (p=0.007) on day 14 p.i. (Figure 4a). 
These results suggested that infection with the Cosmopolitan genotype induced higher 
levels of neutralizing antibodies to the Asian I genotype. In group 4 and group 5 
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marmosets, the levels of neutralizing antibodies to all three genotypes of DENV-2 did 
not differ on day 14 p.i. (Figure 4b-c).  
 
In contrast, following primary DENV-1 infection, neutralizing antibodies to all 
three genotypes of DENV-2 (Cosmopolitan, Asian I, and Asian/American genotypes) 
were absent in group 1 and group 2 marmosets on day 0 (prior to virus inoculation), as 
well as on days 4, 7, and 14 p.i. (Figure 4d-e). These results confirmed that neutralizing 
antibodies induced during primary DENV-1 infection did not neutralize heterologous 
serotype (DENV-2). 
 
3.1.2 Levels of neutralizing antibodies to DENV-2 genotypes following secondary 
infection with homologous and heterologous DENV-2 genotype 
Four groups of marmosets were used in the study to determine levels of 
genotype-specific and genotype cross-reactive neutralizing antibodies to DENV-2 
Cosmopolitan, Asian I, and American/Asian genotypes following secondary infection 
with homologous and heterologous DENV-2 genotype. Group 6, group 7 and group 8 
consisted of marmosets that were inoculated with homologous DENV-2 genotype in 
secondary infection. Group 9 consisted of marmosets that were inoculated with 
heterologous DENV-2 genotype in secondary infection.  
 
Following secondary infection with homologous genotype, in group 6 and 
group 7 marmosets, neutralizing antibodies to three genotypes of DENV-2 
(Cosmopolitan, Asian I, and Asian/American genotypes) were absence or at low levels 
prior to virus inoculation (day 0), but the neutralizing antibodies levels were rapidly 
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increased from day 7 p.i. (Figure 5a-b). The levels of neutralizing antibodies to three 
genotypes of DENV-2 did not differ between genotypes from days 0-14 p.i. 
Interestingly, in group 8 marmosets, neutralizing antibodies to three genotypes of 
DENV-2 were detected prior to virus inoculation (day 0), and the levels increased from 
day 7 p.i. (Figure 5c). Levels of genotype-specific neutralizing antibodies to the 
Asian/American genotype were significantly higher than the levels of genotype cross-
reactive neutralizing antibodies to the Cosmopolitan and Asian I genotypes on days 0, 
4, 7, and 14 p.i. (pday0=0.047, pday4=0.048, pday7=0.042, and pday14=0.027 for the 
Cosmopolitan genotype, and pday0=0.044, pday4=0.044, and pday14=0.027 for the Asian I 
genotype). 
 
Following secondary infection with heterologous genotype (primary DENV-2 
Asian I genotype, secondary DENV-2 Cosmopolitan genotype), the levels of 
neutralizing antibodies in group 9 marmosets rapidly increased from day 7 p.i. (Figure 
5d). Levels of genotype cross-reactive neutralizing antibodies to the Asian/American 
genotype were significantly higher than those to the Cosmopolitan and Asian I 
genotypes on day 7 p.i (p=0.029 and p=0.020, respectively). Levels of genotype cross-
reactive neutralizing antibodies to the Asian I genotype were significantly higher than 
levels of genotype-specific neutralizing antibodies to the Cosmopolitan genotype on 
day 7 p.i. as well (p=0.034). Similarly, levels of genotype cross-reactive neutralizing 
antibodies to the Asian/American genotype were significantly higher than those to the 
Cosmopolitan and Asian I genotypes on day 14 p.i. (p=0.01 and p=0.009, respectively). 
The results suggested that antibodies possessed higher neutralization activities towards 
the Asian/American genotype, which were not used in the primary and secondary 
infection, than towards the Cosmopolitan and Asian I genotypes. After day 365 p.i., 
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neutralizing antibodies to Cosmopolitan, Asian I and Asian/American genotypes were 
still detectable but the levels of neutralizing antibodies between genotypes did not differ.  
 
3.1.3 Levels of neutralizing antibodies to DENV-1 and DENV-2 following secondary 
infection with homologous and heterologous serotype  
Two groups of marmosets were used in the study to determine levels of 
neutralizing antibodies to DENV-1 and DENV-2 following secondary infection with 
homologous or heterologous serotype. Group 10 consisted of marmosets that were 
inoculated with DENV-1 GII genotype in primary infection and DENV-1 GI genotype 
in secondary infection. Group 11 consisted of marmosets that were inoculated with 
DENV-2 Cosmopolitan genotype in primary infection and DENV-1 GI genotype in 
secondary infection.  
 
In group 10 marmosets, serotype cross-reactive neutralizing antibodies to three 
genotypes of DENV-2 (Cosmopolitan, Asian I and Asian/American genotypes) were 
absent on days 0, 4, and 7 p.i. (Figure 6a). Low levels of serotype cross-reactive 
neutralizing antibodies to DENV-2 Asian I genotype were detected on day 7 p.i. The 
marmosets demonstrated neutralizing activities to three genotypes of DENV-2 on day 
14 p.i. and the levels of neutralizing antibodies between genotypes did not differ. High 
levels of serotype-specific neutralizing antibodies to DENV-1 were detected in all the 
marmosets on day 14 p.i. (Figure 6b). These results indicate that two inoculation with 
DENV-1 induced serotype cross-reactive neutralizing antibodies to three genotypes of 
DENV-2 (Cosmopolitan, Asian I, and Asian/American genotypes).  
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In group 11 marmoset, levels of neutralizing antibodies to three genotypes of 
DENV-2 (Cosmopolitan, Asian I, and Asian/American genotypes) were low prior to 
virus inoculation (day 0) (Figure 6c). The levels of serotype cross-reactive neutralizing 
antibodies to DENV-2 increased from day 7 p.i. The levels of serotype cross-reactive 
neutralizing antibodies to three genotypes of DENV-2 did not differ on day 14 p.i. 
(Figure 6c). Serotype-specific neutralizing antibodies to DENV-1 were detected on day 
7 p.i. (Figure 6d). The levels of neutralizing antibodies to the previously infecting 
serotypes (DENV-2) were, however, higher than those to the currently infecting 
serotype (DENV-1) (Figure 6c and 6d). This antibody response pattern demonstrates 
the antigenic sin phenomenon.  
 
3.1.4 Levels of neutralizing antibodies to DENV-2 genotypes in marmosets that were 
inoculated with candidate DENV-1 and DENV-2 vaccines 
Live-attenuated vaccine candidates and four groups of marmosets were used in 
the study to determine the levels of neutralizing antibodies to DENV-2 genotypes 
following inoculation with candidate DENV-1 and DENV-2 vaccines. Group 13 
consisted of marmosets that were immunized with DENV-1 16007 PDK-13 (GII 
genotype) vaccine strain and group 14 consisted of marmosets that were immunized 
with DENV-2 16881 PDK-53 (Asian I genotype) vaccine strain. Group 15 and group 
16 consisted of marmosets that were immunized with candidate DENV-1 or DENV-2 
vaccine strain in primary infection and then inoculated with homologous serotype in 
secondary infection.  
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In group 13 marmosets that were inoculated with DENV-1 16007 PDK-13 
(DENV-1 GII genotype) vaccine strain, levels of serotype cross-reactive neutralizing 
antibody to three genotypes of DENV-2 (Cosmopolitan, Asian I, and Asian/American 
genotypes) were absent from days 0-14 p.i. (Figure 7a). In group 14 marmosets, one 
marmoset that was inoculated with DENV-2 16881 PDK-53 (DENV-2 Asian I 
genotype) vaccine strain, however, demonstrated neutralizing antibodies to DENV-2 
Cosmopolitan, Asian I and Asian/American genotypes on day 14 p.i. (Figure 7b). 
 
In group 15 marmosets, following inoculation with DENV-1 GI genotype in 
secondary infection, serotype cross-reactive neutralizing antibodies to three genotypes 
of DENV-2 (Cosmopolitan, Asian I, and Asian/American genotypes) were detected on 
day 14 p.i. (Figure 7c).  These results were consistent with those results shown in Figure 
3a, and indicated that two inoculation with DENV-1 induced serotype cross-reactive 
neutralizing antibodies which neutralized heterologous serotype, DENV-2. In group 16 
marmosets, following inoculation with DENV-2 Cosmopolitan genotype in secondary 
infection, neutralizing antibodies to three genotypes of DENV-2 were detected from 
day 7 (Figure 7d). The levels of genotype cross-reactive neutralizing antibodies to 
Asian/American genotype were significantly higher than those to Cosmopolitan and 
Asian I genotypes on day 14 p.i., p=0.005 and p=0.003, respectively.  
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3.1.5 Levels of neutralizing antibodies to DENV-1, DENV-2, DENV-3, and DENV-4 
following tertiary DENV infection 
Two groups of marmosets were used in the study to determine the neutralizing 
antibodies patterns between marmosets that were inoculated with clinically isolated 
DENV strain (parent strain) and those that were inoculated with candidate vaccine 
strain following tertiary infection. Group 12 consisted of marmosets that were first 
inoculated with DENV-2 16881 strain (Asian I genotype) in primary infection, and then 
inoculated with DENV-2 Cosmopolitan genotype in secondary infection, and then 
inoculated with DENV-1 GI genotype in tertiary infection. Group 17 consisted of 
marmosets that were first inoculated with DENV-2 16881 PDK-53 vaccine strain 
(Asian I genotype) in primary infection, and then inoculated with DENV-2 
Cosmopolitan genotype in secondary infection, and then inoculated with DENV-1 GI 
genotype in tertiary infection. 
 
In group 12 marmosets (inoculated with the parent strain), neutralizing antibodies 
to DENV-2 Cosmopolitan, Asian I, and Asian/American genotypes were detected prior 
to virus inoculation (on day 0) and the levels increased from day 4 p.i. (Figure 8a). 
Levels of neutralizing antibodies to the Asian/American genotype were significantly 
higher than those to the Cosmopolitan and Asian I genotypes on days 4, 7 and 14 p.i. 
(pday4=0.029, pday7=0.017, and pday14=0.0013 for the Cosmopolitan genotype, and 
pday4=0.029, pday7=0.034, and pday14=0.0013 for the Asian I genotype). Serotypspecific 
neutralizing antibodies to DENV-1 were detected on day 14 p.i. (Figure 8b).  Serotype 
cross-reactive neutralizing to non-infecting serotypes (DENV-3 and DENV-4) were 
detected on day 14 p.i. (Figure 8c). 
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In group 17 marmosets (inoculated with the candidate DENV-2 vaccine strain), 
neutralizing antibodies to DENV-2 Cosmopolitan, Asian I, and Asian/American 
genotypes were detected prior to virus inoculation (on day 0), and the levels increased 
from day 7 p.i. (Figure 8d). Neutralizing antibodies to three genotypes of DENV-2 were 
at similar levels among genotypes from days 0-14 p.i. Serotype-specific neutralizing 
antibodies to DENV-1 were detected in one of the marmosets on day 14 p.i. (Figure 
8e). Interestingly, cross-reactive neutralizing antibodies to DENV-3, non-infecting 
serotype, were detected in one of the marmoset on day 14 p.i., but not to DENV-4 
(Figure 8f).  
 
3.2. DENV specific IgM and IgG antibodies responses 
Presence of DENV-specific IgM and IgG antibodies were determined in groups A, 
B, C, D, E, F, and G marmosets on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 9).  
 
In primary infection, presence of DENV-specific IgM antibodies in group A and 
group B marmosets were detected from days 4-14 p.i. (Figure 9a-b). In secondary 
infection with homologous serotype, levels of DENV-specific IgM antibodies in group 
C and group D marmosets were below the detection baseline from days 0-14 p.i. (Figure 
9c-d). In secondary infection with heterologous infection, presence of DENV-specific 
IgM antibodies in group E marmosets were detected from days 7-14 p.i. (Figure 9e). In 
tertiary infection, one marmoset in group F marmoset demonstrated DENV-specific 
IgM antibodies from days 0-14 p.i, but the other marmoset demonstrated DENV-
specific IgM antibodies from days 7-14 p.i., (Figure 9f). Presence of DENV-specific 
IgM antibodies in group G marmosets were detected from days 4-14 p.i. (Figure 9g). 
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 In primary infection, presence of DENV-specific IgG antibodies in group A and 
group B marmosets were detected from days 10-14 p.i. (Figure 9h-i). Presence of 
DENV-specific IgG antibodies in secondary infection with homologous serotype 
(group C and D marmosets), in secondary infection with heterologous (group E 
marmosets), and in tertiary infection (group F and group G marmosets) were detected 
from days 0-14 p.i. (Figure 9j-n).  
 
3.3. Presence of NS1 antigen 
 
Presence of NS1 antigen was determined in groups A, B, C, D, E, F, and G 
marmosets on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 10). In primary infection (group A 
and group B marmosets), NS1 antigen was detected from days 2-10 p.i. (Figure 10a-b). 
In secondary infection with homologous serotype (group C and group D marmosets), 
NS1 antigen was absent from days 0-14 p.i. (Figure 10c-d). Interestingly, in secondary 
infection with heterologous serotype (group E marmosets), and in tertiary infection 
(group F and group G marmosets), NS1 antigen was detected from days 2-10 p.i. 
(Figure 10e-g).  
 
3.4. Levels of viremia 
Viral RNA (vRNA) copy numbers and infectious virus titers were determined in 
groups A, B, C, D, E, F, and G marmosets on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 11). 
In primary infection, vRNA copy numbers were detected in group A and group B 
marmosets from days 2-10 p.i., and peaked on day 4 p.i. (Figure 11a-b). In group A 
marmosets, infectious virus titers were detected from days 2-7 p.i. (Figure 11f). In 
group B marmosets, infectious virus titers were detected from days 4-7 p.i. (Figure 11g). 
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In secondary infection with homologous serotype, vRNA copy numbers and infectious 
viruses were not detected in group C and group D marmosets. However, in secondary 
infection with heterologous serotype, vRNA copy numbers and infectious virus were 
detected in group E marmoset from days 2-7 p.i. (Figure 11c and 11h). In tertiary 
infection, vRNA copy numbers and infectious virus were detected in group F marmoset 
from days 2-7 p.i. and days 4-7 p.i., respectively (Figure 11d and 11i). In group G 
marmosets, vRNA copy numbers and infectious virus were detected from days 2-10 p.i. 
(Figure 11e and 11j).  
 
3.5. Levels of immune-related genes 
3.5.1 CD3 levels in primary, secondary, and tertiary DENV infections 
Levels of CD3 were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 12).  Differences in the levels of CD3 on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a reference. 
In primary infection, the levels of CD3 did not differ in group A marmosets from days 
0-14 p.i. (Figure 12a). Interestingly, in group B marmosets, the levels of CD3 were 
significantly increased on days 2 and 7 p.i. (p=0.0087 and p=0.0061, respectively) 
(Figure 12b). In secondary infection with homologous serotype, the levels of CD3did 
not differ in group C marmosets from days 0-14 p.i. (Figure 12c). In group D marmosets, 
the levels of CD3 significantly increased on day 2 p.i., p=0.0276 (Figure 12d). In 
secondary infection with heterologous serotype, the levels of CD3did not differ in 
group E marmosets from days 0-14 p.i. (Figure 12e). In tertiary infection, the levels of 
CD3 significantly increased in group F marmosets on day 14 p.i., (p=0.0018), but the 
levels did not differ in group G marmosets from days 0-14 p.i. (Figure 12f-g).  
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3.5.2 CD4 levels in primary, secondary, and tertiary DENV infection 
Levels of CD4 were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 13).  Differences in the levels of CD4 on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a reference. 
In primary infection, the levels of CD4 did not differ in group A marmosets from days 
0-14 p.i. but the levels significantly increased in group B marmosets on day 7 p.i., 
p=0.0307 (Figure 13a-b). In secondary infection with homologous serotype, the levels 
of CD4 did not differ in group C and group D marmosets from days 0-14 p.i. (Figure 
13c-d). In secondary infection with heterologous serotype, the levels of CD4 
significantly decreased in group E marmosets on day 4 p.i., p=0.0274 (Figure 13e). In 
tertiary infection, the levels of CD4 did not diffed in group F marmosets from days 0-
14 p.i., but the levels significantly decreased in group G marmosets on day 14 p.i. 
(Figure 13f-g).  
 
3.5.3 CD8 levels in primary, secondary, and tertiary DENV infection 
Levels of CD8 were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 14). Differences in the levels of CD8 on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a reference. 
In primary infection, the levels of CD8significantly decreased in group A marmosets 
on day 4 p.i. (p=0.0070), but the levels did not differ in group B marmosets from days 
0-14 p.i.  (Figure 14a-b). In secondary infection with homologous serotype, the levels 
of CD8 did not differ in group C and group D marmosets from days 0-14 p.i. (Figure 
14c-d). In secondary infection with heterologous serotype, the levels of CD8 
significantly decreased in group E marmosets on day 14 p.i., p=0.0069 (Figure 14e). In 
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tertiary infection, the levels of CD8 did not differ in group F marmosets from days 0-
14 p.i., but the levels significantly decreased on day 2 p.i. (p=0.0060) and significantly 
increased on day 7 p.i. (p=0.0099) in group F marmosets (Figure 14f-g).   
 
3.5.4 IFN levels in primary, secondary, and tertiary DENV infection 
Levels of IFN were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 15). Differences in the levels of IFN on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a reference. 
In primary infection, the levels of IFNsignificantly decreased in group A marmosets 
on days 2, 4, and 7 p.i. (pday2=0.0104, pday4=0.0012, pday7=0.0240), but the levels did 
not differ in group B marmosets from days 0-14 p.i. (Figure 15a-b). In secondary 
infection with homologous serotype, the levels of IFNdid not differ in group C and 
group D marmosets from days 0-14 p.i. (Figure 15c-d). In secondary infection with 
heterologous serotype, the levels of IFN did not differ in group E marmosets from days 
0-14 p.i. (Figure 15e). In tertiary infection, the levels of IFN did not differ in group F 
marmosets from day 0-14 p.i. but the levels significantly decreased in group G 
marmosets on day 2 p.i. (p=0.0354) (Figure 15f-g).  
 
3.5.5 IL-1 levels in primary, secondary, and tertiary DENV infection 
Levels of IL-1 were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 16). Differences in the levels of IL-1 on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a reference. 
In primary infection, the levels of IL-1 significantly decreased in group A marmosets 
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on days 4, 7, and 14 p.i. and in group B marmosets on days 7 and 14 p.i. (pday4=0.0108, 
pday7=0.0246, pday14=0.0030 for group A marmosets, pday7=0.0051, pday14=0.0194 for 
group B marmosets) (Figure 16a-b). In secondary infection with homologous serotype, 
the levels of IL-1 did not differ in group C and group D marmosets from days 0-14 
p.i. (Figure 16c-d). In secondary infection with heterologous serotype, levels of IL-1 
significantly decreased in group E marmosets on days 7 and 10 p.i. (pday7=0.0383, 
pday10=0.0475) (Figure 16e). In tertiary infection, the levels of IL-1 significantly 
decreased in group F and group G marmosets on days 7, 10, and 14 p.i. (pday7=0.0321, 
pday10=0.0473, pday14=0.0256 for group F, and pday7=0.0014 pday10=0.0447, 
pday14=0.0020 for group G) (Figure 16f-g).  
 
3.5.6 IL-2 levels in primary, secondary, and tertiary DENV infection 
Levels of IL-2 were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 17). Differences in the levels of IL-2 on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those on day 0 as a reference. 
In primary infection, the levels of IL-2 did not differ in group A and group B marmosets 
from days 0-14 p.i. (Figure 17a-b). In secondary infection with homologous serotype, 
the levels of IL-2 did not differ in group C and group D marmosets from days 0-14 p.i. 
(Figure 17c-d). In secondary infection with heterologous serotype, the levels of IL-2 
significantly decreased in group E marmosets on day 7 p.i., p=0.0140 (Figure 17e). In 
tertiary infection, the levels of IL-2 significantly decreased in group F marmosets on 
day 14 p.i. (p=0.0377) but the levels did not differ in group G marmosets from days 0-
14 p.i. (Figure 17f-g). 
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3.5.7 IL-10 levels in primary, secondary, and tertiary DENV infection 
Levels of IL-10 were determined in groups A, B, C, D, E, F, and G marmosets 
on days 0, 2, 4, 7, 10, and 14 p.i. (Figure 18). Differences in the levels of IL-10 on days 
2, 4, 7, 10, and 14 p.i. were determined and compared with those day 0 as a reference. 
In primary infection, the levels of IL-10 did not differ in group A and group B 
marmosets from days 0-14 p.i. (Figure 18a-b). In secondary infection with homologous 
serotype, levels of IL-10 significantly decreased in group C marmoset on days 7, 10, 
and 14 p.i. (pday7=0.0391, pday10=0.0242, pday14=0.0084), but the levels did not differ in 
group D marmosets from days 0-14 p.i. (Figure 18c-d). In secondary infection with 
heterologous serotype, the levels of IL-10 did not differ in group E marmosets from 
days 0-14 p.i. (Figure 18e). In tertiary infection, the levels of IL-10 did not differ in 
group F and group G marmosets from days 0-14 p.i (Figure 18f-g).  
 
3.5.8 Relationship between levels of CD8 and levels of viremia 
Levels of CD8 were compared side-by-side with levels of viremia (viral RNA 
copies number and infectious virus titers) in group A marmosets (primary infection), 
group E marmosets (secondary infection with heterologous serotype), and group G 
marmosets (tertiary infection) (Figure 19). In group A marmosets, the levels of CD8 
decreased on day 4 p.i when the levels of viremia increased (Figure 19a-c). In group E 
marmosets, the levels of CD8 increased on day 14 p.i. when viremia was cleared 
(Figure 19d-f). In group G marmosets, the levels of CD8decreased on day 2 p.i when 
viremia levels increased, and the levels of CD8 increased on day 7 p.i. when viremia 
levels decreased (Figure 19g-i).  
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3.6. Figures 
 
 
Figure 4. Levels of neutralizing antibodies to DENV-2 Cosmopolitan, Asian I and 
Asian/American genotypes following primary DENV-1 and DENV-2 infection on 
days 0, 4, 7, and 14 p.i. Neutralizing antibodies titers of marmosets that were 
inoculated with: (a) DENV-2 Cosmopolitan genotype, (b) DENV-2 Asian I genotype, 
(c) DENV-2 Asian/American genotype, (d) DENV-1 GI genotype, (e) DENV-1 GII 
genotype. Asterisks (*) indicates significant differences (p<0.05) in titers of 
neutralizing antibodies between genotypes.
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Figure 5. Levels of neutralizing antibodies to DENV-2 Cosmopolitan, Asian I and 
Asian/American genotypes following secondary infection with homologous and 
heterologous genotype of DENV-2 on days 0, 4, 7, and 14 p.i. Neutralizing antibodies 
titers of marmosets with: (a) Homologous DENV-2 Cosmopolitan genotype infection, 
(b) Homologous DENV-2 Asian I genotype infection, (c) Homologous DENV-2 
Asian/American genotype infection, (d) Heterologous genotype DENV-2 infection. 
Asterisks (*) indicates significant differences (p<0.05) in titers of neutralizing 
antibodies between genotypes.  
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Figure 6. Levels of neutralizing antibodies to DENV-1 and DENV-2 Cosmopolitan, 
Asian I and Asian/American genotypes following secondary infection with 
homologous and heterologous serotype of DENV on days 0, 4, 7, and 14 p.i. 
Neutralizing antibodies titers of marmosets with: (a) Homologous serotype DENV-1 
infection, (b) Neutralizing antibodies titers to DENV-1 during homologous serotypes 
DENV-1 infection, (c) Heterologous serotype DENV-1 infection, (d) Neutralizing 
antibodies titers to DENV-1 during heterologous serotypes DENV-1 infection.
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Figure 7. Levels of neutralizing antibodies to DENV-2 Cosmopolitan, Asian I and 
Asian/American genotypes in marmosets that were inoculated with candidate 
DENV-1 and DENV-2 vaccine strain on days 0, 4, 7, and 14 p.i. Neutralizing 
antibodies titers in marmosets inoculated with: (a) DENV-1 16007 PDK-13 vaccine 
strain, (b) DENV-2 16881 PDK-53 vaccine strain, (c) DENV-1 16007 PDK-13 vaccine 
strain in primary infection and DENV-1 GI genotype in secondary infection, (d) 
DENV-2 16881 PDK-53 vaccine strain in primary infection and DENV-2 
Cosmopolitan genotype in secondary infection. Asterisks (*) indicates significant 
differences (p<0.05) in neutralizing antibodies titers between genotypes.
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Figure 8. Levels of neutralizing antibodies to DENV-2 Cosmopolitan, Asian I, and 
Asian/American genotypes, DENV-1, DENV-3, and DENV-4 following tertiary 
infection on days 0, 4, 7, and 14 p.i. (a) Marmosets that were inoculated with DENV-
2 16881 strain (Asian I genotype) in primary infection, inoculated with the DENV-2 
Cosmopolitan genotype in secondary infection, and inoculated with DENV-1 GI 
genotype in tertiary infection. (b) Neutralizing antibodies titers to DENV-1 in the same 
marmosets in (a). (c) Neutralizing antibodies titers to DENV-3 and DENV-4 in the 
same marmosets in (a). (d) Marmosets that were inoculated with DENV-2 16881 PDK-
53 vaccine strain (Asian I genotype) in primary infection, inoculated with DENV-2 
Cosmopolitan genotype in secondary infection, and inoculated with DENV-1 GI 
genotype in tertiary infection. (e) Neutralizing antibodies titers to DENV-1 in the same 
marmosets in (d). (f) Neutralizing antibodies titers to DENV-3 and DENV-4 in the same 
marmosets in (d). Asterisks (*) indicates significant differences (p<0.05) in neutralizing 
antibodies titers between genotypes. AI indicates DENV-2 Asian I genotype. CM 
indicates DENV-2 Cosmopolitan genotype.
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Figure 9. Levels of DENV-specific IgM and IgG antibody in plasma samples of 
groups A, B, C, D, E, F, and G marmosets on days 0, 2, 4, 7, 10, and 14 p.i. (a-g) 
Positive negative (P/N) ratio of DENV-specific IgM antibody in groups A, B, C, D, E, 
F, and G marmosets, respectively. (h-n) P/N ratio of DENV-specific IgG antibody in 
groups A, B, C, D, E, F, and G marmosets, respectively. Dash line indicates the baseline 
of positive value for P/N ratio. Day 0 was defined as day of virus inoculation. 
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Figure 10. Levels of NS1 antigen in plasma samples of groups A, B, C, D, E, F, and 
G marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Levels of NS1 antigen in marmosets 
that were inoculated with: (a) DENV-2 Asian I genotype, (b) DENV-2 Asian/American 
genotype, (c) Secondary infection with homologous serotype, DENV-2 Asian I 
genotype, (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype, (f) Tertiary infection with DENV-1 GI genotype, (g) Tertiary infection 
with DENV-1 GI genotype. Dash line indicates the baseline of positive value for P/N 
ratio. Day 0 defined as day of virus inoculation.  
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Figure 11. Levels of viral RNA copy numbers and infectious virus titers in plasma 
samples of groups A, B, E, F, and G marmosets on days 0, 2, 4, 7, 10, and 14 p.i. 
Levels of vRNA copy numbers in marmosets that were inoculated with: (a) Primary 
DENV-2 Asian I genotype, (b) Primary DENV-2 Asian/American genotype, (c) 
Secondary infection with heterologous DENV-1 serotype, (d) Tertiary DENV-1 GI 
genotype, (e) Tertiary DENV-1 GIV genotype; Levels of infectious virus titers in 
marmosets that were inoculated with : (f) Primary DENV-2 Asian I genotype, (g) 
Primary DENV-2 Asian/American genotype, (h) Secondary infection with 
heterologous DENV-1 serotype, (i) Tertiary DENV-1 GI genotype, (j) Tertiary DENV-
1 GIV genotype. Filled bar indicates levels of viral RNA copy numbers, log10 genome 
copies/ml. Pattern bar indicates titer of DENV, pfu/ml. 
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Figure 12. Levels of CD3 in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Levels of CD3 in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype, (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype, (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GIV genotype. 
Bar represents mean expression levels + standard deviation (SD). Asterisk (*) indicates 
significant differences (p<0.05) in levels of CD3, compared with day 0 as a reference.  
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Figure 13. Levels of CD4 in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2 4, 7, 10, and 14 p.i. Levels of CD4 in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype, (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI serotype, (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GII genotype. 
Bar represents mean expression levels + SD. Asterisk (*) indicates significant 
differences (p<0.05) in levels of CD4, compared with day 0 as a reference.  
0 2 4 7 10 14
0
2
4
6
Day (Post-inoculation)
Group G
(DENV2 Asian I - DENV2 Cosmopolitan 
- D1GIV)
*
0 2 4 7 10 14
0
2
4
6
Day (Post-inoculation)
M
e
a
n
 2
-Δ
Δ
C
t 
 (
C
D
4
)
Group F
(DENV2 Asian I-DENV2 Cosmopolitan 
- DENV1 GI)
0 2 4 7 14
0
2
4
6
M
e
a
n
 2
-Δ
Δ
C
t 
 (
C
D
4
)
Group A
(DENV2 Asian I)
Primary
Secondary
Tertiary
a b
c d e
f g
0 2 4 7 14
0
2
4
6
Group B
(DENV2 Asian/American)
*
0 2 4 7 10 14
0
2
4
6
M
e
a
n
 2
-Δ
Δ
C
t 
 (
C
D
4
)
Group C
(DENV2 Asian I-DENV2 Asian I)
0 2 4 7 10 14
0
2
4
6
Group D
(DENV2 Asian/American-
DENV2 Asian/American)
0 2 4 7 10 14
0
2
4
6
Day (Post-inoculation)
Group E
(DENV2 Cosmopolitan-DENV1 GI)
*
  54 
 
Figure 14. Levels of CD8 in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Levels of CD8 in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GIV genotype. 
Bar represents mean expression levels +SD. Asterisk (*) indicates significant 
differences (p<0.05) in levels of CD8, compared with day 0 as a reference. 
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Figure 15. Levels of IFN in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Levels of IFN in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype, (d) Secondary infection with homologous serotype, DENV-1 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype, (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GIV genotype. 
Bar represents mean expression levels +SD. Asterisk (*) indicates significant 
differences (p<0.05) in levels of CD8, compared with day 0 as a reference. 
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Figure 16. Levels of IL-1 in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Levels of IL-1 in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype, (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype, (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GIV genotype. 
Bar represents mean expression levels +SD. Asterisk (*) indicates significant 
differences (p<0.05) in levels of IL-1, compared with day 0 as a reference. 
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Figure 17. Levels of IL-2 in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Levels of IL-2 in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype, (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype, (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GIV genotype. 
Bar represents mean expression levels +SD. Asterisk (*) indicates significant 
differences (p<0.05) in levels of IL-2, compared with day 0 as a reference. 
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Figure 18. Levels of IL-10 in PBMC samples of groups A, B, C, D, E, F, and G 
marmosets on days 0, 2 4, 7, 10, and 14 p.i. Levels of IL-10 in marmosets that were 
inoculated with: (a) Primary DENV-2 Asian I genotype, (b) Primary DENV-2 
Asian/American genotype, (c) Secondary infection with homologous serotype, DENV-
2 Asian I genotype, (d) Secondary infection with homologous serotype, DENV-2 
Asian/American genotype, (e) Secondary infection with heterologous serotype, DENV-
1 GI genotype, (f) Tertiary DENV-1 GI genotype, (g) Tertiary DENV-1 GIV genotype. 
Bar represents mean expression levels +SD. Asterisk (*) indicates significant 
differences (p<0.05) in levels of IL-10, compared with day 0 as a reference.
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Figure 19. Side by side comparison between levels of CD8 and levels of viremia 
of group A, E, and G marmosets on days 0, 2, 4, 7, 10, and 14 p.i. Group A of 
primary marmosets: (a) Levels of CD8 (b) Viral RNA copy numbers, (c) Infectious 
virus titers. Group E of secondary infection with heterologous serotype (d) Levels of 
CD8, (e) Viral RNA copy numbers, (f) Infectious virus titers. Group G of tertiary 
infection marmosets (g) Levels of CD8, (h) Viral RNA copy numbers (i) Infectious 
virus titers. Open bar indicates CD8levels. Filled bar indicates viral RNA copy 
numbers. Pattern bar indicates infectious virus titers. Green arrowhead indicates 
decreased in expression levels and red arrowhead indicates increased in expression 
levels.  
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CHAPTER 4: DISCUSSION 
 
In this present study, levels of genotype-specific and genotype cross-reactive 
neutralizing antibodies to DENV-2 were analyzed in primary, secondary, and tertiary 
DENV infection in common marmosets. Neutralizing antibodies that were induced 
during primary DENV-2 infection with a single genotype neutralized multiple 
genotypes within DENV-2. In marmosets that were inoculated with Asian I and 
Asian/American genotypes, levels of neutralizing antibodies to three genotypes of 
DENV-2 were at similar. Levels of neutralizing antibodies to heterologous Asian I 
genotype appeared to be higher than those to homologous Cosmopolitan genotype in 
marmosets that were inoculated with Cosmopolitan genotype. 
 
In secondary infection with homologous genotype, genotype-specific and genotype 
cross-reactive neutralizing antibodies to DENV-2 Cosmopolitan, Asian I, and 
Asian/American genotypes were at similar levels. In case of secondary infection with 
homologous Asian/American genotype, levels of neutralizing antibodies to 
homologous genotype were higher than those to heterologous genotypes. Interestingly, 
in secondary infection with heterologous genotype, levels of neutralizing antibodies to 
non-infecting genotype (Asian/American genotype) were higher than those to infecting 
genotype (Cosmopolitan and Asian I genotypes). These results were consistent with 
those obtained in secondary infection using candidate vaccine strains (Figure 7d) and 
in tertiary infection (Figure 8a). Differences in levels of neutralizing antibodies against 
three genotypes were most prominent when levels of the neutralizing antibody were 
high (PRNT50=640-20480). The results suggest that heterogeneity in antigenic 
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molecules between genotypes may lead to induction of higher levels of neutralizing 
antibodies to the epitope of the third genotype (Asian/American genotype in this study), 
and synergize the neutralization of the third virus. However, elevated levels of 
neutralizing antibody to the Asian/American genotype were not observed one year after 
secondary infection, when the levels of neutralizing antibodies already decreased. 
These data suggest that subset of antibodies that neutralized the Asian/American 
genotype better than those to the Cosmopolitan and Asian genotypes were diluted 
during these period, and that neutralization activities of these subsets of antibodies were 
only observed when the overall neutralizing antibodies activities were at high levels.  
 
Following primary DENV-1 infection, neutralizing antibodies did not neutralize 
heterologous serotype, DENV-2. However, following secondary DENV-1 infection, 
neutralizing antibodies that were induced were serotype cross-reactive and able to 
neutralize DENV-2. Nonetheless, levels of neutralizing antibodies to homologous 
serotype (DENV-1) were higher compared to heterologous serotype (DENV-2). It has 
been reported that following DENV infection, even though neutralizing antibodies that 
were induced are serotype cross-reactive, levels of neutralizing antibodies against the 
infecting serotype were remained the highest92–95. These results suggest that serotype 
cross-reactive neutralizing antibodies are induced at some level, and that a robust 
secondary homologous immune response (mean secondary homologous DENV-1 
PRNT50=907; primary DENV-1 PRNT50=60) may cause serotype cross-reactive 
neutralizing antibodies response more apparent. While infection with a single serotype 
typically leads to high levels of serotype-specific antibodies, it is likely that two 
infections with homologous serotype, serotype cross-reactive antibodies may be 
boosted to threshold levels and enable to cross-neutralize other serotypes. In this regard, 
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secondary homologous infection may partially contribute to serotype cross-protection 
in dengue hyper-endemic areas, due to higher risk of repeated exposure to the same 
serotype.  
 
Sequential infection induced broad cross-reactive neutralizing antibodies that 
neutralized multiple serotypes including non-infecting serotypes in short period of time. 
Cross-reactive neutralizing antibodies induced during sequential infection generally 
possess broad cross-reactivity and able to neutralized multiple serotypes including non-
infecting serotypes, as demonstrated in studies on DEN cohort patients 11,95–98 Notably, 
during secondary infection with heterologous serotype, levels of neutralizing antibodies 
against prior serotype were higher than those against the newly infected serotype. 
Although high levels of neutralizing antibodies to previously infecting serotypes 
persisted up to 9 months after sequential infection, the neutralizing antibodies level 
decreased over time30. Antibody decay and waning immunity induced susceptibility to 
infection with heterologous DENV serotype because of the partial protection and 
antibody-dependent enhancement of infection8,48,99.  
 
Levels of neutralizing antibodies to DENV-2 genotypes during homologous and 
heterologous infection differed. Homogeneity and heterogeneity of infecting genotype 
influence levels and cross-reactivity of neutralizing antibodies induced in subsequent 
infection because antigenic differences among genotypes lead to differences in 
antibody neutralization6,11,45. Antigenic differences may cause structural changes on 
viral protein that will modify the antibody binding site and affect the ability of 
neutralizing antibodies to confer protection against heterologous genotype12,13. The 
next step would be to expand the understanding on the spectrum of neutralizing 
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antibody patterns after homologous and heterologous infection, using combination of 
different genotype and serotype of DENV. While clinical trials of vaccine candidate 
demonstrated that vaccine is immunogenic in humans and animal models, there were 
limited data available on the variability of neutralizing activity against different 
genotypes within serotype. The variability in the levels of neutralizing antibodies 
between genotypes suggest that sequence heterogeneity between genotypes could result 
in complex cross-reactive immune responses; leading to distinct variable patterns of 
neutralizing antibodies among genotypes11,18,100–102. Similarly, marmosets inoculated 
with a candidate vaccine demonstrated variability in neutralizing antibodies patterns 
comparable to those inoculated with parental strain; suggesting that while attenuation 
leads to decreased pathogenicity, immunogenicity patterns between genotypes are 
retained.  
 
Infection with different genotypes and serotypes of DENV induced different levels 
of viremia. Primary infection with DENV-2 Asian I genotype induced longer duration 
of viremia in marmosets than those with DENV-2 Asian/American genotype infection.  
Similar results were observed in tertiary infection marmosets. Infection with DENV-1 
GIV genotype induced longer duration of viremia in marmosets than those with DENV-
1 GI genotype. These results suggested that virus fitness and pathogenicity among 
genotypes differed. Studies on DEN patients reported that infection with Asian I 
genotype induced higher levels of viremia in dengue patients than those that were 
infected with Asian/American infection16,19,20. 
 
In secondary infection, viremia was detected in marmosets with heterologous 
serotype infection but not in marmosets with homologous serotype infection. The 
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results indicated that neutralizing antibodies are induced during primary infection to 
confer protection against homologous serotypes but did not protect against 
heterologous serotype. Results from secondary infection were in accordance with 
assumption that neutralizing antibodies induced after primary DENV infection will 
confers life-long protection against infection with homologous serotype but protection 
against heterologous serotype is short-lived. Nonetheless, since the secondary 
infections with homologous serotype were in fact homologous genotype infection, it is 
not clear whether neutralizing antibodies were induced during primary infection will 
offer complete protection against heterologous genotype. Incomplete protection against 
heterologous genotype incidence during DENV-2 outbreak were reported in Peru13. 
The next step would be to explore the ability of neutralizing antibodies to offer 
protection during heterologous genotype infection.  
 
 As most studies on cell-mediated immunity during DENV infection were 
performed by the comparison of data collected from health individual, acute DEN 
patient, and severe DEN patient, studies on correlation between antigenic differences 
and immune-related genes during DENV infection are still limited. The present study 
demonstrated that inoculation with different genotypes and serotypes of DENV induced 
different levels of CD3, CD4, CD8, IFN, IL-2 and IL-10. Interestingly, the levels 
of IL-1 decreased in all marmosets that developed viremia following DENV 
inoculation. It has been reported that expression levels of immune-related genes were 
varied according to disease severity, rate of viral replication, and viral fitness5,103.  
 
 Although relationship between antigenic differences and immune-related genes 
remain inconclusive, two genes, CD8 and IL-1demonstrating interesting results. In 
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the present study, levels of CD8decreased in early days after infection (days 2-4 p.i.) 
but then increased on later days after infection (days 7-14 p.i). It was reported that 
number of CD8+ T cells were low in days 1-4 after onset of symptoms, but then 
increased at late phase of disease in acute dengue patients104. Further comparison 
suggested that levels of CD8 were inversely correlated with levels of viremia. 
Depletion of CD8+ T cells in mouse model resulted in increased DENV infection105. 
These results suggested that the CD8+ T cells have protective roles in the host defense 
during DENV infection, and that CD8+ cells may have been activated to control the 
viral replication 104–106. 
 
Levels of IL-1 is reduced in the marmosets that developed viremia following 
DENV inoculation. While one study reported that IL-1 did not play an important role 
in the dengue pathogenesis, other studies reported levels of IL-1 were elevated in 
dengue patients than those in healthy individuals107–110. The antibody-dependent 
enhancement were reported involved in facilitate the elevation of the IL-
1levelsIncreased levels of IL-1 were associated with vascular permeability, 
hypotension, and hemoconcentration in DEN patients110. In the present study, no 
marmosets that developed viremia showed vascular permeability symptoms. Decreased 
levels of IL-1 in marmosets maybe associated in the absence of vascular permeability 
symptoms.  
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 This study highlighted that infection with different genotype and serotype of 
DENV induce different levels of neutralizing antibodies, viremia and immune related 
genes in marmosets. Differences in neutralizing antibodies pattern, viremia levels, and 
immune responses may have been caused by antigenic differences in DENV genotypes 
and serotypes. Antigenic differences in DENV likely plays an important role in disease 
severity, viral fitness, and ability to change the viral protein that affect the neutralizing 
activities of antibodies12,14.
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CHAPTER 5: CONCLUSION AND FUTURE RESEARCH 
 
 Levels and patterns of genotype-specificity and genotype cross-reactivity in 
neutralizing antibodies response to genotypes of DENV-2 are different in primary, 
secondary, and tertiary infection. These differences in induced neutralizing antibodies 
are caused by the antigenic differences of infected DENV. Antigenic differences among 
genotypes affect the induction of neutralizing antibodies, and eventually levels of 
protection against heterologous genotypes and serotypes of DENV. In addition, 
antigenic differences may contribute to disease severity, epidemic cycling and viral 
evolution. To maximize the efficacy of DEN vaccine, it is important to further 
understand the spectrum of neutralizing antibodies in relation to protection capabilities 
against different genotypes and serotypes. Furthermore, understanding of antigenic 
differences among genotypes within each of 4 serotypes is also important, since 
different genotypes induce different levels of neutralizing antibodies. Based on this 
understanding, identification of DENV strains that able to induce similar levels of 
neutralizing antibodies against homologous or heterologous genotypes should be 
addressed in DENV vaccine development study.  
   
 The relationship between antigenic differences and immune responses are 
remain inconclusive. Nonetheless, it is worth addressing the possibilities of the use of 
T-cell markers and cytokines as biomarkers in predicting disease severity. Research on 
the identification of biomarkers for this purpose is also important. The biomarkers will 
be able to evaluate the prognosis, and improved the treatment and management of DEN 
patients. 
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